Key Points
- Director Michael Harrington bought 5,000 Elanco shares at an average price of $21.82, investing $109,100 and increasing his ownership by 3.95% to 131,451 shares.
- Elanco’s latest quarter beat expectations, with adjusted EPS of $0.34 versus the $0.27 consensus and revenue of $1.37 billion, up 10.2% year over year. The company guided to full-year 2026 EPS of $1.10–$1.16.
- Analysts maintain a broadly positive view, with a “Moderate Buy” consensus rating and an average price target of $29.09 versus the stock’s reported $22.52 opening price.
Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) Director Michael Harrington bought 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the purchase, the director owned 131,451 shares in the company, valued at $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Elanco Animal Health Stock Performance
Shares of NYSE ELAN opened at $22.52 on Friday. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a market cap of $11.25 billion, a P/E ratio of -54.93, a P/E/G ratio of 1.33 and a beta of 1.67. The business's 50 day moving average is $24.56 and its two-hundred day moving average is $24.03. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.31 billion. During the same period in the prior year, the business earned $0.26 earnings per share. Elanco Animal Health's revenue for the quarter was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in ELAN. NewEdge Advisors LLC lifted its stake in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after purchasing an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Elanco Animal Health in the 2nd quarter worth approximately $38,000. Root Financial Partners LLC lifted its position in shares of Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock worth $40,000 after buying an additional 592 shares during the period. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $41,000. Finally, Torren Management LLC acquired a new stake in Elanco Animal Health in the 4th quarter valued at $46,000. Institutional investors and hedge funds own 97.48% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 22nd. Wall Street Zen cut Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a report on Sunday, May 24th. Citigroup lifted their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. Finally, UBS Group boosted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.09.
Read Our Latest Report on Elanco Animal Health
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
